M
Michael J. Birrer
Researcher at University of Arkansas for Medical Sciences
Publications - 579
Citations - 64433
Michael J. Birrer is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 102, co-authored 554 publications receiving 54218 citations. Previous affiliations of Michael J. Birrer include University of Texas MD Anderson Cancer Center & University of Arkansas at Little Rock.
Papers
More filters
Book ChapterDOI
Akute und subakute Extremitätenischämie: Katheterthrombolyse und -thrombusaspiration
TL;DR: The Kathetertherapie gewinnt zunehmende Bedeutung im Therapiekonzept der akuten und subakuten Extremitatenischamie, insbesondere wenn alle Moglichkeiten der Katheterapie in Kombination eingesetzt werden.
Journal ArticleDOI
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Marcela G. del Carmen,Jeffrey G. Supko,Nora Horick,J. Alejandro Rauh-Hain,Rachel M. Clark,Susana M. Campos,Carolyn N. Krasner,T. Atkinson,Michael J. Birrer +8 more
TL;DR: The objective of this phase 1 and 2 trial was to identify the appropriate dose of combined carboplatin and pralatrexate for patients with recurrent, platinum‐sensitive ovarian, fallopian tube, and primary peritoneal cancer.
Book ChapterDOI
Regulation of Gastrin Releasing Peptide Gene Expression
TL;DR: SCLC growth in vitro and in vivo is blocked by synthetic BN/GRP receptor antagonists and the inositol-1,4,5-trisphosphate released elevates cytosolic calcium and the diacylglycerol released activated protein kinase C.
Proceedings ArticleDOI
76 Patients (PTS) with recurrent gynecologic cancer whose tumors have activating wnt pathway mutations respond better to DKN-01, a DICKKOPF-1 (DKK1) inhibitor
Rebecca C. Arend,Cesar M. Castro,Ursula A. Matulonis,Erika Hamilton,Camille C. Gunderson,Kristopher Lybarger,H Goodman,Linda R. Duska,Haider Mahdi,Adam C. ElNaggar,M Kagey,Lisa Barroilhet,William H. Bradley,J Sachdev,David M. O'Malley,C Sirard,Michael J. Birrer +16 more
TL;DR: D and D + P have activity in pts with recurrent gyn cancers; the role of Wnt/β-catenin pathway activation as a potential biomarker for response is currently under study.
Journal ArticleDOI
CD157 in Ovarian Carcinoma: How Does It Help Us?
TL;DR: An intriguing story involving CD157 is presented that suggests a role for this protein in the progression and aggressiveness of ovarian tumors and could confer increased invasive capacity to some ovarian cancers and therefore could indicate a particular line of therapy.